Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and raises the price target from $30 to $33.
April 24, 2024 | 9:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Day One Biopharmaceutical and raises the price target from $30 to $33.
The upgrade in price target by a reputable analyst like Ami Fadia from Needham is a strong positive signal for investors, indicating a bullish outlook on the stock. This could lead to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100